<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJS</journal-id>
<journal-id journal-id-type="hwp">spijs</journal-id>
<journal-id journal-id-type="nlm-ta">Int J Surg Pathol</journal-id>
<journal-title>International Journal of Surgical Pathology</journal-title>
<issn pub-type="ppub">1066-8969</issn>
<issn pub-type="epub">1940-2465</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1066896911417711</article-id>
<article-id pub-id-type="publisher-id">10.1177_1066896911417711</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Metaplastic Carcinoma of the Breast With Dominant Squamous and Sebaceous Differentiation in the Primary Tumor and Osteochondroid Metaplasia in a Distant Metastasis</article-title>
<subtitle>Report of a Case With Review of Sebaceous Differentiation in Breast Tumors</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Carlucci</surname><given-names>Maria</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911417711">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Iacobellis</surname><given-names>Michela</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911417711">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Colonna</surname><given-names>Fulvia</given-names></name>
<degrees>HT</degrees>
<xref ref-type="aff" rid="aff1-1066896911417711">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Marseglia</surname><given-names>Mario</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896911417711">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gambarotti</surname><given-names>Marco</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-1066896911417711">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Giardina</surname><given-names>Carmela</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-1066896911417711">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Bisceglia</surname><given-names>Michele</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-1066896911417711">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-1066896911417711"><label>1</label>Umberto I Hospital, Altamura, Italy</aff>
<aff id="aff2-1066896911417711"><label>2</label>Rizzoli Orthopaedic Institute, Bologna, Italy</aff>
<aff id="aff3-1066896911417711"><label>3</label>University of Bari, Bari, Italy</aff>
<aff id="aff4-1066896911417711"><label>4</label>IRCC Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy</aff>
<author-notes>
<corresp id="corresp1-1066896911417711">Michele Bisceglia, Division of Anatomic Pathology, IRCCS Casa Sollievo della Sofferenza Hospital, 71013 San Giovanni Rotondo, Italy Email: <email>bismi@libero.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>20</volume>
<issue>3</issue>
<fpage>284</fpage>
<lpage>296</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Metaplastic breast carcinoma is an uncommon tumor that develops from conventional ductal mammary carcinoma, usually consisting of squamous and/or spindle cell components and/or mesenchymal elements. Although several morphological subtypes of metaplastic breast carcinoma are known, sebaceous metaplasia has not yet been described in this context. The authors report a case of an 84-year-old woman with a huge, ulcerated primary tumor in her left breast that had already been present for 10 years. Pulmonary and bone metastases and a tumor nodule in the contralateral breast were also detected at the time of admission. Left simple mastectomy was performed. Histological examination of the tumor revealed metaplastic carcinoma consisting of ductal carcinoma, which immunohistochemically exhibited a triple-negative immunoprofile, along with dominant areas of squamous and sebaceous differentiation. Adjuvant chemotherapy was subsequently given with partial regression of the systemic metastases. Seven months after surgery and diagnosis, a new, rapidly growing, large soft tissue metastatic tumor appeared in the intramuscular compartment of the patient’s right thigh, which was removed and histologically examined. Morphologically this metastatic tumor showed ductal adenocarcinoma along with areas of sebaceous differentiation and, in addition, osteochondroid metaplasia. Immunohistochemically, unlike the primary, this tumor expressed HER-2. The case is presented because of its rarity, and sebaceous differentiation is also proposed as a novel type of metaplasia in this context, expanding the spectrum of the histological patterns of metaplastic breast carcinoma. The literature concerning breast sebaceous lesions is reviewed, and the hypothetical biological mechanisms responsible for the tumor pathogenesis in this case are discussed.</p>
</abstract>
<kwd-group>
<kwd>metaplastic carcinoma</kwd>
<kwd>carcinoma with squamous differentiation</kwd>
<kwd>carcinoma with sebaceous differentiation</kwd>
<kwd>carcinoma with osteochondroid metaplasia</kwd>
<kwd>triple negative breast cancer</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1066896911417711" sec-type="intro">
<title>Introduction</title>
<p><italic>Metaplastic carcinoma of the breast is a general term referring to a (morphologically) heterogeneous group of neoplasms generally characterized by an intimate admixture of adenocarcinoma with dominant areas of spindle cell, squamous, and/or mesenchymal differentiation</italic>.<sup><xref ref-type="bibr" rid="bibr1-1066896911417711">1</xref></sup> According to the proportion and/or admixture of the histological components involved, 2 main subcategories are identified, the purely epithelial and the mixed epithelial and mesenchymal.<sup><xref ref-type="bibr" rid="bibr1-1066896911417711">1</xref><xref ref-type="bibr" rid="bibr2-1066896911417711"/>-<xref ref-type="bibr" rid="bibr3-1066896911417711">3</xref></sup> The epithelial component of metaplastic carcinoma of the breast includes several morphological subtypes, such as squamous cell carcinoma, low- grade adenosquamous carcinoma, mucoepidermoid carcinoma, adenocarcinoma with spindle cell metaplasia (biphasic carcinoma), carcinoma with chondroid and/or osseous metaplasia, and other forms of carcinosarcoma.<sup><xref ref-type="bibr" rid="bibr1-1066896911417711">1</xref><xref ref-type="bibr" rid="bibr2-1066896911417711"/>-<xref ref-type="bibr" rid="bibr3-1066896911417711">3</xref></sup> Monophasic low-grade fibromatosis-like carcinoma<sup><xref ref-type="bibr" rid="bibr4-1066896911417711">4</xref>,<xref ref-type="bibr" rid="bibr5-1066896911417711">5</xref></sup> and high-grade spindle cell metaplastic carcinoma, including a subset with myoepithelial differentiation,<sup><xref ref-type="bibr" rid="bibr6-1066896911417711">6</xref></sup> have been added also to the list. Notably (pseudo-)sarcomatous areas in metaplastic carcinoma of the breast can retain an epithelial immunophenotype.<sup><xref ref-type="bibr" rid="bibr7-1066896911417711">7</xref></sup></p>
<p>We report a case of metaplastic ductal adenocarcinoma of the breast with dominant squamous and sebaceous differentiation in the primary and which exhibited osteochondroid metaplasia in a distant metastasis.</p>
</sec>
<sec id="section2-1066896911417711" sec-type="cases">
<title>Case Report</title>
<sec id="section3-1066896911417711">
<title>Clinical History</title>
<p>An 84-year-old woman without a family history of cancer was admitted to the Umberto I hospital, Altamura, Italy, with a huge ulcerated mass, encompassing the 2 upper quadrants of her left breast. The tumor had been present and growing slowly for about 10 years. Her medical history revealed controlled diabetes and arterial hypertension. Breast examination disclosed a greasy, ulcerated, and vegetating left breast mass measuring 12 × 10 cm, with no axillary lymphadenopathy. Another palpable mass was also clinically detected in the right breast, which was suspected of being malignant. A total body computed tomography scan showed multiple metastases in the lung and in the D7 vertebral body. A simple left mastectomy was performed, following which the patient received an oral daily dose of 1300 mg twice a day for 2 weeks followed by a 1-week rest period, given for a total of 6 cycles during 18 weeks. A biopsy of the right breast tumor was not taken. This right breast tumor and the pulmonary and vertebral metastases partially regressed after chemotherapy, but 7 months later another deeply located intramuscular mass appeared in the anterior compartment of the patient’s right thigh. This secondary lesion grew progressively to a maximum diameter of 17 cm, which was surgically excised at the Rizzoli Orthopaedic Institute, Bologna, Italy, 14 months postmastectomy.</p>
</sec>
<sec id="section4-1066896911417711">
<title>Pathological Features: Primary Tumor</title>
<p>Grossly, the breast tumor was huge and hour-glass shaped with a round polypoid, ulcerated component on the external surface, 12 cm in size, which was in continuity with an intraparenchymal mainly solid mass with delineated borders, 7 cm in its main dimension, which showed alternating yellowish and whitish areas on the cut surface (<xref ref-type="fig" rid="fig1-1066896911417711">Figures 1A</xref> and <xref ref-type="fig" rid="fig1-1066896911417711">1B</xref>). On gross examination, it was evident that the intraparenchymal portion of the tumor extended deeply coming close to the surgical resection margin. The surgical specimen was extensively sampled and routinely processed. Histologically, the tumor exhibited both in its outer and inner components foci with ductal, partly cribriform, differentiation (20% to 30%) admixed with dominant areas of squamous (~30%) and sebaceous (~30%) differentiation. Squamous differentiation was mainly keratinizing and focally merged with a minor component with spindle cell morphology (~10%). Small foci of adenosquamous differentiation were also seen (~5%). Taking all these features into account a morphological final diagnosis of “purely epithelial metaplastic carcinoma” was established (<xref ref-type="fig" rid="fig2-1066896911417711">Figures 2A</xref> to <xref ref-type="fig" rid="fig2-1066896911417711">2F</xref>). Immunohistochemically, the usual prognostic and predictive markers were investigated, and both the ductal and the metaplastic carcinoma components of the tumor were found to be diffusely negative for both female steroid hormone receptors (estrogen receptor [ER], progesterone receptor [PR]) and human epidermal growth factor receptor-2 (HER-2). The proliferating fraction evaluated by means of MIB-1 antibody to Ki-67 nuclear antigen was 30%. In addition, androgen receptors (ARs) were also negative. For the sake of completeness, high molecular weight cytokeratin (HMW-CK), p63, epithelial membrane antigen (EMA), and GCDFP-15 were tested with the following results: HMW-CK was positive both in tumor areas with ductal differentiation and in those with squamous and spindle cell phenotype and negative in the clusters of sebaceous cells; p63 was positive in the tumor cells with squamous, squamoid and spindle cell appearances and negative in the tumor foci with ductal or gland-like features and sebaceous differentiation; EMA was surprisingly negative in the ductal-type and well-differentiated cribriform tumor component but was positive in the clusters of sebaceous cells (<xref ref-type="fig" rid="fig3-1066896911417711">Figures 3A</xref> to <xref ref-type="fig" rid="fig3-1066896911417711">3D</xref>). GCDFP-15 was negative throughout. Details of the antibodies used are listed in <xref ref-type="table" rid="table1-1066896911417711">Table 1</xref>.</p>
<fig id="fig1-1066896911417711" position="float">
<label>Figure 1.</label>
<caption><p>(A) Mastectomy specimen. Exophytic tumor protruding above the surrounding skin. (B) Cut surface reveals a solid tumor with foci of necrosis.</p></caption>
<graphic xlink:href="10.1177_1066896911417711-fig1.tif"/>
</fig>
<fig id="fig2-1066896911417711" position="float">
<label>Figure 2.</label>
<caption><p>(A and B) Well-differentiated ductal carcinoma with cribriform features. (C and D) Squamous metaplasia with foci of keratinization. (E and F) Ductal carcinoma with gland-like, squamoid, and sebaceous differentiation. Insets in panels E and F: Details of sebaceous differentiation (Diastase-periodic acid Schiff).</p></caption>
<graphic xlink:href="10.1177_1066896911417711-fig2.tif"/>
</fig>
<fig id="fig3-1066896911417711" position="float">
<label>Figure 3.</label>
<caption><p>(A) Immunoreactivity of the ductal component with antibody CK-34βE12 to high molecular weight cytokeratins. (B) Scattered immunoreactivity for p63 in squamoid areas (sebaceous foci and gland-like structures are negative). The right half and the left half correspond to panels E and F of <xref ref-type="fig" rid="fig2-1066896911417711">Figure 2</xref>. (C and D) Sebaceous cells are immunopositive for epithelial membrane antigen (EMA). Surprisingly, the ductal cells are EMA negative.</p></caption>
<graphic xlink:href="10.1177_1066896911417711-fig3.tif"/>
</fig>
<table-wrap id="table1-1066896911417711" position="float">
<label>Table 1.</label>
<caption><p>Antibodies and Protocols Used for Immunohistochemistry in Primary Breast Carcinoma<sup><xref ref-type="table-fn" rid="table-fn2-1066896911417711">a</xref></sup></p></caption>
<graphic alternate-form-of="table1-1066896911417711" xlink:href="10.1177_1066896911417711-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Antibodies to</th>
<th align="center">Clone/Polyclonal</th>
<th align="center">Source</th>
<th align="center">Dilution/Ag Retrieval</th>
<th align="center">Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytokeratin HMW</td>
<td>34BE12</td>
<td>Novocastra, Newcastle-upon-Tyne, UK</td>
<td>Prediluited/water bath 98°C in PBS pH 9</td>
<td>Pos. (squamous component)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Pos. (ductal component)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Neg. (sebaceous component)</td>
</tr>
<tr>
<td>p63</td>
<td>BC4A4</td>
<td>DakoCytomation, Glostrup, Denmark</td>
<td>1:50/water bath 98°C in EDTA pH 8</td>
<td>Pos. (squamous component)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Neg. (ductal component)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Neg. (sebaceous component)</td>
</tr>
<tr>
<td>EMA</td>
<td>E29</td>
<td>DakoCytomation</td>
<td>Prediluted/proteinase K</td>
<td>Pos. (sebaceous cells only)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Neg. (ductal component)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Neg. (sebaceous component)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Neg. (squamous component)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Pos. (normal breast serving as IC)</td>
</tr>
<tr>
<td>α-SMA</td>
<td>1A4</td>
<td>NeoMarkers, Fremont, CA</td>
<td>1:200/none</td>
<td>Pos. (spindle cell foci only)</td>
</tr>
<tr>
<td>S-100 protein</td>
<td>Polyclonal</td>
<td>DakoCytomation</td>
<td>Prediluted/water bath 98°C in PBS pH 6</td>
<td>Neg. (all components)</td>
</tr>
<tr>
<td>CEA</td>
<td>II-7<sup><xref ref-type="table-fn" rid="table-fn3-1066896911417711">b</xref></sup></td>
<td>DakoCytomation</td>
<td>Prediluted/water bath 98°C in PBS pH 9</td>
<td>Neg. (all components)</td>
</tr>
<tr>
<td>Synaptophysin</td>
<td>SY38</td>
<td>DakoCytomation</td>
<td>1:500/water bath 98°C in EDTA pH 8</td>
<td>Neg. (all components)</td>
</tr>
<tr>
<td>ER</td>
<td>1D5</td>
<td>DakoCytomation</td>
<td>Prediluted/water bath 98°C in PBS pH 6</td>
<td>Neg. (all components)</td>
</tr>
<tr>
<td>PR</td>
<td>PgR636</td>
<td>DakoCytomation</td>
<td>Prediluted/water bath 98°C in PBS pH 6</td>
<td>Neg. (all components)</td>
</tr>
<tr>
<td>HER2</td>
<td>Polyclonal</td>
<td>DakoCytomation</td>
<td>Hercept test<sup><xref ref-type="table-fn" rid="table-fn3-1066896911417711">b</xref></sup></td>
<td>Neg. (all components)</td>
</tr>
<tr>
<td>AR</td>
<td>AR441</td>
<td>DakoCytomation</td>
<td>1:40/water bath 98°C in EDTA pH 8</td>
<td>Neg. (all components)</td>
</tr>
<tr>
<td>Ki-67 Antigen</td>
<td>MIB1</td>
<td>DakoCytomation</td>
<td>Prediluted/water bath 98°C in PBS pH 6</td>
<td>Nuclear staining (mean LI: 30% of tumor cell nuclei)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1066896911417711">
<p>Abbreviations: GCDFP-15, gross cystic disease fluid protein; HMW, high molecular weigth; EMA, epithelial membrane antigen; SMA, smooth muscle actin; CEA, carcinoembryonic antigen; ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; EDTA, ethylenediaminetetraacetic acid. Pos., positivity. Neg., negativity; PBS, phosphate buffered saline; IC, internal control; LI, labeling index.</p>
</fn>
<fn id="table-fn2-1066896911417711">
<label>a</label>
<p>All the immunohistochemical stainings were performed using the labeled streptavidin–biotin peroxidase complex system with diaminobenzidine as a chromogen according to the manufacturer’s recommendation in a DAKO Autostainer (Dako).</p>
</fn>
<fn id="table-fn3-1066896911417711">
<label>b</label>
<p>HER2 immunostaining was performed according to the instructions enclosed to the “HercepTest” kit.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-1066896911417711">
<title>Pathological Features: Soft Tissue Metastasis</title>
<p>The huge soft tissue mass showed well-circumscribed margins but was unencapsulated. It was firm in consistency and gritty on sectioning. Histologically the tumor showed mixed epithelial and mesenchymal differentiation with areas of evident ductal–not otherwise specified (NOS) carcinoma, and squamous (nonkeratinizing), sebaceous, and diffuse osteochondroid metaplastic changes. The ductal-NOS areas were graded as poorly differentiated (G3), whereas the mesenchymal component was well differentiated and benign looking (<xref ref-type="fig" rid="fig4-1066896911417711">Figures 4A</xref> to <xref ref-type="fig" rid="fig4-1066896911417711">4D</xref>). Immunohistochemically, the tumor was CK7+/CK20− as to the ductal tumor component and diffusely negative for ER and PR, but strongly positive for HER-2/Neu (Dako score 3+; <xref ref-type="fig" rid="fig4-1066896911417711">Figures 4E</xref> and <xref ref-type="fig" rid="fig4-1066896911417711">4F</xref>). The mesenchymal osteochondroid component of the tumor was vimentin positive and cytokeratins (wide spectrum) negative. The proliferation index as assessed with MIB-1 antibody was evaluated at 80% in the ductal component. See <xref ref-type="table" rid="table2-1066896911417711">Table 2</xref> for details.</p>
<fig id="fig4-1066896911417711" position="float">
<label>Figure 4.</label>
<caption><p>(A) Metastatic carcinoma with epithelial and metaplastic osseous features. (B) Area with osteochondroid metaplastic changes. (C) Ductal-type component. (D) Ductal-type component with extensive sebaceous differentiation. (E) Immunoreactivity for CK7 of a ductal area with sebaceous differentiation. (F) HER2/Neu immunopositivity in the ductal component with partly positive clusters of sebaceous cells. Metaplastic breast carcinomas are usually negative for HER2, and the primary tumor in this case was negative.</p></caption>
<graphic xlink:href="10.1177_1066896911417711-fig4.tif"/>
</fig>
<table-wrap id="table2-1066896911417711" position="float">
<label>Table 2.</label>
<caption><p>Antibodies and Protocols Used for Immunohistochemistry in Soft Tissue Metastasis<sup><xref ref-type="table-fn" rid="table-fn5-1066896911417711">a</xref></sup></p></caption>
<graphic alternate-form-of="table2-1066896911417711" xlink:href="10.1177_1066896911417711-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Antibody to</th>
<th align="center">Clone</th>
<th align="center">Source</th>
<th align="center">Dilution/Pretreatment</th>
<th align="center">Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vimentin</td>
<td>V9</td>
<td>V9 Dakocytomation, Glostrup, Denmark</td>
<td>1:400/not required</td>
<td>Neg. (epithelial component)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Pos. (mesenchymal component)</td>
</tr>
<tr>
<td>Cytokeratin w.s.</td>
<td>MNF116</td>
<td>MNF116 Dakocytomation</td>
<td>1:1200/proteinase K</td>
<td>Pos. (epithelial component)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Neg. (mesenchymal component)</td>
</tr>
<tr>
<td>Cytokeratin 7</td>
<td>OV-TL</td>
<td>Dakocytomation</td>
<td>1:400/proteinase K</td>
<td>Pos. (ductal-NOS component)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Pos. (sebaceous cells)</td>
</tr>
<tr>
<td>Cytokeratin 20</td>
<td>K20.8</td>
<td>Dakocytomation</td>
<td>1:50/proteinase K</td>
<td>Diffuse negativity</td>
</tr>
<tr>
<td>ER</td>
<td>1D5</td>
<td>Dakocytomation</td>
<td>1:50/water bath 95°C, in citrate buffer pH 8</td>
<td>Diffuse negativity</td>
</tr>
<tr>
<td>PR</td>
<td>PgR636</td>
<td>Dakocytomation</td>
<td>1:50/water bath 95°C, in citrate buffer pH 8</td>
<td>Diffuse negativity</td>
</tr>
<tr>
<td>HER2</td>
<td>Polyclonal</td>
<td>Dakocytomation</td>
<td>1:200/water bath 95°C, in citrate buffer pH 8</td>
<td>Pos. (+++)<sup><xref ref-type="table-fn" rid="table-fn6-1066896911417711">b</xref></sup> (ductal component)
</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Mean Pos. ~40% of tumor cells</td>
</tr>
<tr>
<td>Ki-67 antigen</td>
<td>MIB1</td>
<td>Dakocytomation</td>
<td>1:100/30 min at 95°C, in citrate buffer pH 8</td>
<td>High tumor proliferation fraction (mean LI: 80% of tumor cell nuclei)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1066896911417711">
<p>Abbreviations: ER, estrogen receptors; PR, progesterone receptors; HER2, human epidermal growth factor receptor-2; Neg., negativity; Pos., positivity; LI, labeling index.</p>
</fn>
<fn id="table-fn5-1066896911417711">
<label>a</label>
<p>All the immunohistochemical stainings were performed in a Dako Autostainer using the Dako Real detection system streptavidin–biotin alkaline phosphatase with fast red as a chromogen, except for HER2 where the streptavidin–biotin peroxidase complex system was used.</p>
</fn>
<fn id="table-fn6-1066896911417711">
<label>b</label>
<p>The membrane staining pattern was scored according to the HercepTest criteria (Dako).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-1066896911417711">
<title>Follow-Up</title>
<p>Following the soft tissue metastasis resection, the patient received radiation therapy targeted to the surgical site and to a vertebral lesion, which responded favorably. However, her lung metastases progressed and the patient died in cachectic state 19 months after the initial diagnosis of breast cancer.</p>
</sec>
</sec>
<sec id="section7-1066896911417711" sec-type="discussion">
<title>Discussion</title>
<p>Metaplastic invasive carcinoma of the breast is a special type/category of invasive ductal carcinoma, accounting for less than 1% of such tumors,<sup><xref ref-type="bibr" rid="bibr1-1066896911417711">1</xref>,<xref ref-type="bibr" rid="bibr8-1066896911417711">8</xref></sup> which develops from conventional mammary adenocarcinomas via transepithelial differentiation and epithelial–mesenchymal phenotypic transition,<sup><xref ref-type="bibr" rid="bibr9-1066896911417711">9</xref></sup> following molecular genetic alterations associated with regulation or downregulation of epithelial phenotypes as well as with synthesis and remodeling of extracellular matrix and cell-to-matrix adhesion.<sup><xref ref-type="bibr" rid="bibr10-1066896911417711">10</xref></sup> Metaplastic carcinoma of the breast is generally characterized by the coexistence of ductal carcinoma with areas of squamous and/or epithelial spindle cell differentiation and/or benign or malignant mesenchymal (<italic>mostly osseous and/or chondroid</italic>) areas with or without an intervening undifferentiated spindle cell tumor component (<italic>“mixed subcategory of metaplastic breast carcinoma”</italic>).<sup><xref ref-type="bibr" rid="bibr1-1066896911417711">1</xref>,<xref ref-type="bibr" rid="bibr3-1066896911417711">3</xref></sup> In addition, purely epithelial metaplastic carcinoma, such as squamous, adenosquamous, mucoepidermoid, and metaplastic spindle cell carcinoma, can also occur in the breast (<italic>“purely epithelial subcategory of metaplastic breast carcinoma”</italic>).<sup><xref ref-type="bibr" rid="bibr1-1066896911417711">1</xref>,<xref ref-type="bibr" rid="bibr3-1066896911417711">3</xref></sup> Sebaceous differentiation is not listed in either standard surgical pathology or in specialized breast pathology textbooks as one of the several possible cytologic patterns of metaplastic carcinoma. <sup><xref ref-type="bibr" rid="bibr1-1066896911417711">1</xref>,<xref ref-type="bibr" rid="bibr3-1066896911417711">3</xref>,<xref ref-type="bibr" rid="bibr8-1066896911417711">8</xref>,<xref ref-type="bibr" rid="bibr11-1066896911417711">11</xref>,<xref ref-type="bibr" rid="bibr12-1066896911417711">12</xref></sup> Although extremely rare, sebaceous differentiation in the breast, similar to squamous metaplasia, should not be very surprising since the breast is of modified sweat gland origin, and both squamous and sebaceous differentiations are inherent in the adnexa and skin. Sebaceous differentiation associated with squamous metaplasia has also been produced experimentally in a nonmetastatic rat mammary epithelial cell line transfected with DNA from a metastatic rat mammary cell line.<sup><xref ref-type="bibr" rid="bibr13-1066896911417711">13</xref></sup> Based on a computerized search of the literature (PubMed/Medline), and to the best of our knowledge, sebaceous differentiation in human breast pathology has been reported in 9 cases of adenoid cystic carcinoma,<sup><xref ref-type="bibr" rid="bibr14-1066896911417711">14</xref></sup> 5 cases of ductal carcinoma,<sup><xref ref-type="bibr" rid="bibr15-1066896911417711">15</xref><xref ref-type="bibr" rid="bibr16-1066896911417711"/>-<xref ref-type="bibr" rid="bibr17-1066896911417711">17</xref></sup> (1 of which reported as a sebaceous-like lipid-rich carcinoma),<sup><xref ref-type="bibr" rid="bibr16-1066896911417711">16</xref></sup> 4 cases of adenomyoepithelioma,<sup><xref ref-type="bibr" rid="bibr18-1066896911417711">18</xref>,<xref ref-type="bibr" rid="bibr19-1066896911417711">19</xref></sup> and 2 cases of benign intraductal papilloma,<sup><xref ref-type="bibr" rid="bibr20-1066896911417711">20</xref>,<xref ref-type="bibr" rid="bibr21-1066896911417711">21</xref></sup> sometimes in association with squamous,<sup><xref ref-type="bibr" rid="bibr12-1066896911417711">12</xref>,<xref ref-type="bibr" rid="bibr18-1066896911417711">18</xref>,<xref ref-type="bibr" rid="bibr21-1066896911417711">21</xref></sup> adenosquamous,<sup><xref ref-type="bibr" rid="bibr14-1066896911417711">14</xref></sup> and squamous and myoepithelial<sup><xref ref-type="bibr" rid="bibr22-1066896911417711">22</xref></sup> differentiation. Another case of sebaceous metaplasia in an intraductal papilloma of the breast, in absence of squamous metaplasia, was seen by one of us (MB, unpublished observation—case also reviewed by M. Michal, Sikl’s Department of Pathology, Plzen, Czech Republic). As a consequence of the above assertions, we view <italic>sebaceous differentiation in ductal carcinoma</italic> as an adjunctive cytologic pattern, expanding the heterogeneous morphological spectrum of the metaplastic category of breast cancer. It is still reasonable to keep as a separate special type those <italic>pure sebaceous tumors</italic> arising in the mammary gland parenchyma, of which 7 cases have been reported so far,<sup><xref ref-type="bibr" rid="bibr12-1066896911417711">12</xref>,<xref ref-type="bibr" rid="bibr23-1066896911417711">23</xref><xref ref-type="bibr" rid="bibr24-1066896911417711"/><xref ref-type="bibr" rid="bibr25-1066896911417711"/>-<xref ref-type="bibr" rid="bibr26-1066896911417711">26</xref></sup> the first 4 cases reported as a sebaceous variant of lipid-rich carcinoma.<sup><xref ref-type="bibr" rid="bibr26-1066896911417711">26</xref></sup> Parenthetically, 3 cases of sebaceous carcinoma arising from the skin of the breast, including the nipple,<sup><xref ref-type="bibr" rid="bibr27-1066896911417711">27</xref><xref ref-type="bibr" rid="bibr28-1066896911417711"/>-<xref ref-type="bibr" rid="bibr29-1066896911417711">29</xref></sup> have also been described, both within<sup><xref ref-type="bibr" rid="bibr27-1066896911417711">27</xref>,<xref ref-type="bibr" rid="bibr29-1066896911417711">29</xref></sup> and outside<sup><xref ref-type="bibr" rid="bibr28-1066896911417711">28</xref></sup> the clinical context of the Muir-Torre syndrome, and these are more appropriately included in the general category of cutaneous sebaceous carcinoma (extraocular subset<sup><xref ref-type="bibr" rid="bibr30-1066896911417711">30</xref>,<xref ref-type="bibr" rid="bibr31-1066896911417711">31</xref></sup>). <xref ref-type="table" rid="table3-1066896911417711">Table 3</xref> reviews the main clinicopathologic features of all these sebaceous lesions or lesions with sebaceous differentiation so far published in the literature.</p>
<table-wrap id="table3-1066896911417711" position="float">
<label>Table 3.</label>
<caption><p>Clinicopathologic Features of Breast Tumors With Sebaceous Differentiation and pure Sebaceous Tumors of Breast: Literature Review</p></caption>
<graphic alternate-form-of="table3-1066896911417711" xlink:href="10.1177_1066896911417711-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Reference</th>
<th align="center">Patient Gender and Age/Tumor Side and Size</th>
<th align="center">Histological Features; Sebaceous Cells (%)</th>
<th align="center">Staging</th>
<th align="center">HR and HER2; LI or S-Phase</th>
<th align="center">Follow-Up (Months)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6"><bold>(Intraparenchymal) Breast carcinomas with sebaceous differentiation</bold></td>
</tr>
<tr>
<td>Prescott et al (1922)<sup><xref ref-type="bibr" rid="bibr22-1066896911417711">22</xref></sup></td>
<td>Female, 74 years/Right, ∅ 5 cm</td>
<td>IDC with squamous, sebaceous and myoepithelial differentiation</td>
<td>Negative LNs</td>
<td>NS</td>
<td>AWNED</td>
</tr>
<tr>
<td/>
<td/>
<td>SC: % NS</td>
<td/>
<td/>
<td>(6 m0)</td>
</tr>
<tr>
<td>Mazzella et al (1995)<sup><xref ref-type="bibr" rid="bibr16-1066896911417711">16</xref></sup></td>
<td>Male, 55 years/Left, ∅ 5 cm</td>
<td>IDC with “lipid-rich sebaceous-like component”</td>
<td>Negative LNs</td>
<td>ER+; PR+</td>
<td>AWNED</td>
</tr>
<tr>
<td/>
<td/>
<td>SC: 25%-75%</td>
<td/>
<td>HER2: NA</td>
<td>(10 mo)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>High S-phase</td>
<td/>
</tr>
<tr>
<td>Varga et al (2000)<sup><xref ref-type="bibr" rid="bibr17-1066896911417711">17</xref></sup></td>
<td>Female, 45 years/Right, ∅ 2.5 cm</td>
<td>IDC with sebaceous differentiation</td>
<td>Negative LNs</td>
<td>ER+; PR+</td>
<td>Skin and bone mets (132 mo)</td>
</tr>
<tr>
<td/>
<td/>
<td>SC: 50%</td>
<td/>
<td>HER2 neg</td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>AR neg</td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>LI Ø 16%</td>
<td/>
</tr>
<tr>
<td>Kinkor et al (2010)<sup><xref ref-type="bibr" rid="bibr15-1066896911417711">15</xref></sup></td>
<td>Female, 51 years/Left, ∅ 1.3 cm</td>
<td>IDC with sebaceous differentiation</td>
<td>Negative LNs</td>
<td>ER+; PR+</td>
<td>AWNED</td>
</tr>
<tr>
<td/>
<td/>
<td>SC: 10%</td>
<td/>
<td>HER2 neg<sup><xref ref-type="table-fn" rid="table-fn8-1066896911417711">a</xref></sup></td>
<td>(19 mo)</td>
</tr>
<tr>
<td/>
<td/>
<td>CEA neg/EMA+</td>
<td/>
<td>MIB-1 Ø 10%</td>
<td/>
</tr>
<tr>
<td>Kinkor et al (2010)<sup><xref ref-type="bibr" rid="bibr15-1066896911417711">15</xref></sup></td>
<td>Female, 62 years/Right, ∅ 2.7 cm</td>
<td>IDC with sebaceous differentiation</td>
<td>Negative sentinel-LN</td>
<td>ER+; PR neg</td>
<td>AWNED</td>
</tr>
<tr>
<td/>
<td/>
<td>SC: 30%</td>
<td/>
<td>HER2 neg<sup><xref ref-type="table-fn" rid="table-fn8-1066896911417711">a</xref></sup></td>
<td>(27 mo)</td>
</tr>
<tr>
<td/>
<td/>
<td>CEA neg/ EMA+</td>
<td/>
<td>MIB-1 = 10%</td>
<td/>
</tr>
<tr>
<td>Kinkor et al (2010)<sup><xref ref-type="bibr" rid="bibr15-1066896911417711">15</xref></sup></td>
<td>Female, 69 years/NS, ∅ 41 cm</td>
<td>IDC with sebaceous differentiation</td>
<td>1 positive LN</td>
<td>ER+; PR neg</td>
<td>NA</td>
</tr>
<tr>
<td/>
<td/>
<td>SC: 40%</td>
<td/>
<td>HER2 neg<sup><xref ref-type="table-fn" rid="table-fn8-1066896911417711">a</xref></sup></td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td>CEA/EMA neg</td>
<td/>
<td>MIB-1 = 10%</td>
<td/>
</tr>
<tr>
<td>Carlucci et al (present case)</td>
<td>Female, 84 years/Left, ∅ &gt;15 cm</td>
<td>Primary: IDC with squamous, sebaceous, spindle and adenosquamous differentiation</td>
<td>Clinically negative</td>
<td>ER neg; PR neg</td>
<td>Deceased</td>
</tr>
<tr>
<td/>
<td/>
<td>ST mets: IDC with sebaceous and ostochondroid differentiation</td>
<td>LNsLung ant bone mets at Dg</td>
<td>Her-2 neg</td>
<td>(22 mo)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>ST mets at 7 mo</td>
<td>AR neg</td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>LI = 30%</td>
<td/>
</tr>
<tr>
<td colspan="6"><bold>(Intraparenchymal) Pure sebaceous breast carcinomas</bold></td>
</tr>
<tr>
<td>van Bogaert and Maldague (1977)<sup><xref ref-type="bibr" rid="bibr26-1066896911417711">26</xref></sup></td>
<td>3 cases: Sex: NS</td>
<td>Invasive sebaceous carcinoma (all 3 cases)</td>
<td>Ns (all 3)</td>
<td>NS (all 3)</td>
<td>(All 3)</td>
</tr>
<tr>
<td/>
<td>(~F)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td>Age: ≥33 to ≤76 years</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td/>
<td>Size: ≥1.2 to ≥3.5 cm</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Tavassoli (1999)<sup><xref ref-type="bibr" rid="bibr12-1066896911417711">12</xref></sup></td>
<td>Female, 46 years/Right, ∅ 7.5 cm</td>
<td>Invasive sebaceous carcinoma with squamoid morules</td>
<td>Negative LNs</td>
<td>ER neg; PR+AR neg</td>
<td>NS</td>
</tr>
<tr>
<td>Hisaoka et al (2006)<sup><xref ref-type="bibr" rid="bibr23-1066896911417711">23</xref></sup></td>
<td>Female, 71 years/Right, ∅ 2.0 cm</td>
<td>Invasive sebaceous carcinoma with focal IHC-NEC differentiation</td>
<td>1 positive LN</td>
<td>ER+; PR+HER2: negAR negLI = 38%</td>
<td>NS</td>
</tr>
<tr>
<td>Murakami et al (2009)<sup><xref ref-type="bibr" rid="bibr24-1066896911417711">24</xref></sup></td>
<td>Female, 50 years/NA, ∅ 2 cm</td>
<td>Invasive sebaceous carcinoma</td>
<td>1 positive LN</td>
<td>ER and PR negAR+LI = 30%</td>
<td>AWNED</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>(24 mo)</td>
</tr>
<tr>
<td>Ramliak et al (2010)<sup><xref ref-type="bibr" rid="bibr25-1066896911417711">25</xref></sup></td>
<td>Female, 85 years/Left, ∅ 7.5 cm</td>
<td>Invasive sebaceous carcinoma</td>
<td>NS (~LN dissection not performed)</td>
<td>ER neg; PR negHer-2 negLI = 25%</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6"><bold>Sebaceous carcinomas of the skin of breast</bold></td>
</tr>
<tr>
<td>Propeck et al (2000)<sup><xref ref-type="bibr" rid="bibr29-1066896911417711">29</xref></sup></td>
<td>Female, 46 years/Right, ∅ 1.4 cm</td>
<td>Cutaneous sebaceous carcinoma (local excision performed)</td>
<td align="center">—</td>
<td>NS</td>
<td>AWNED</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>(6 mo) MTS</td>
</tr>
<tr>
<td>Cibull et al (2008)<sup><xref ref-type="bibr" rid="bibr28-1066896911417711">28</xref></sup></td>
<td>Female, 83 years/Left, ∅ 1 cm</td>
<td>Cutaneous sebaceous carcinoma (local excision performed)</td>
<td align="center">—</td>
<td>NS</td>
<td>AWNED</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>(9 mo)</td>
</tr>
<tr>
<td>Alzaraa et al (2008)<sup><xref ref-type="bibr" rid="bibr27-1066896911417711">27</xref></sup></td>
<td>Female, 43 years/Left, ∅ NS</td>
<td>Cutaneous sebaceous carcinoma (local excision performed)</td>
<td align="center">—</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>MTS</td>
</tr>
<tr>
<td colspan="6"><bold>Sebaceous metaplasia in benign tumors of breast</bold></td>
</tr>
<tr>
<td>Tavassoli et al (1991)<sup><xref ref-type="bibr" rid="bibr19-1066896911417711">19</xref></sup></td>
<td>3 cases: All females</td>
<td colspan="4">Adenomyoepithelioma (cannot exclude the coexistence of other forms of metaplasia, such as apocrine, mucinous, and/or squamous metaplasia)</td>
</tr>
<tr>
<td/>
<td>Age: ≥38 to ≥82 years</td>
<td colspan="4"/>
</tr>
<tr>
<td/>
<td>Side: NS, ∅ ≥1 to ≥7 cm</td>
<td colspan="4"/>
</tr>
<tr>
<td>Jiao et al (2001)<sup><xref ref-type="bibr" rid="bibr21-1066896911417711">21</xref></sup></td>
<td>Female, 70 years/NS, ∅ 4 cm</td>
<td colspan="4">Intraductal Papilloma with foci of squamous and sebaceous metaplasia (local excision)</td>
</tr>
<tr>
<td>Bisceglia (2001)<sup><xref ref-type="table-fn" rid="table-fn9-1066896911417711">b</xref></sup></td>
<td>Female, 43 years/Right, ∅ 2 cm</td>
<td colspan="4">Intraductal papilloma (local excision)</td>
</tr>
<tr>
<td>Gao et al (2007)<sup><xref ref-type="bibr" rid="bibr20-1066896911417711">20</xref></sup></td>
<td>NA/NA</td>
<td colspan="4">Intraductal papilloma (NA)</td>
</tr>
<tr>
<td>Cai et al (2005)<sup><xref ref-type="bibr" rid="bibr18-1066896911417711">18</xref></sup></td>
<td>Female, “elderly”/Right, ∅ 4 cm</td>
<td colspan="4">Intracystic adenomyoepithelioma with foci of squamous and sebaceous metaplasia (mastectomy)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1066896911417711">
<p>Abbreviations: LN, lymph nodes; HR, hormone receptor; ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; HER2, human epidermal growth factor receptor-2; LI, labeling index as assessed with monoclonal antibody to Ki-67 nuclear antigen; S-phase, proliferative fraction as assessed on flow cytometry; Ca, carcinoma; NS, not stated by the reporting authors. Ns, not specified (the 3 cases were included in a wide series of tumors containing cytoplasmic lipids, 3 of which had axillary LFs involved); NA, not available to the authors of this current article; AWNED, alive with no evidence of disease; IHC, immunohistochemistry; NEC, neuroendocrine differentiation; Dg, diagnosis; MTS, clinical context of Muir-Torre syndrome; Mets, Metastases; ∅, main diameter; +, positive; neg, negative.</p>
</fn>
<fn id="table-fn8-1066896911417711">
<label>a</label>
<p>Nonamplified on fluorescent in situ hybridization.</p>
</fn>
<fn id="table-fn9-1066896911417711">
<label>b</label>
<p>Unpublished observation of one of the authors (MB). Case also reviewed by M. Michal (Sikl’s Department of Pathology and Charles University, Plzen, Czech Republic).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The case described herein presents distinctive features regarding the histological composition of the primary tumor, the discordant receptor/HER-2 status of the primary and the metastatic soft tissue tumor, the duration of the primary lesion, and the soft tissue metastasis and its histological composition, all of which will be elaborated on in the following paragraphs.</p>
<p>First, this is only the seventh case of invasive ductal carcinoma of the breast with sebaceous differentiation and the second metaplastic carcinoma showing sebaceous differentiation associated with squamous metaplasia, after the one reported by Prescott et al,<sup><xref ref-type="bibr" rid="bibr22-1066896911417711">22</xref></sup> which in addition also expressed myoepithelial differentiation (<xref ref-type="table" rid="table3-1066896911417711">Table 3</xref>). Although in our case the skin was focally ulcerated and thus in theory one could also consider the possibility of an adnexal skin origin, especially from sebaceous appendages, we did not actually document any features suggesting cutaneous origin. The absence of lobulation and of a nesting architectural pattern, as well as the lack of transition from peripherally placed basal-type sebaceous cells to centrally located clear foamy sebaceous cells, all of which would be expected in (pure) sebaceous tumors, and, in contrast, the alternation of sebaceous foci with areas of conventional ductal carcinoma militate against that possibility. Sebaceous carcinoma of the skin often occurs in the context of Muir-Torre syndrome,<sup><xref ref-type="bibr" rid="bibr31-1066896911417711">31</xref></sup> an autosomal dominant disease caused by germ-line mutations in mismatch repair genes (MSH2 gene and one in the MLH1 gene),<sup><xref ref-type="bibr" rid="bibr32-1066896911417711">32</xref></sup> defined by the joint appearance of at least one sebaceous skin tumor and one internal malignancy,<sup><xref ref-type="bibr" rid="bibr33-1066896911417711">33</xref>,<xref ref-type="bibr" rid="bibr34-1066896911417711">34</xref></sup> a subset of which (associated with colorectal cancer) fulfills the Amsterdam criteria for hereditary nonpoliposis colorectal cancer.<sup><xref ref-type="bibr" rid="bibr32-1066896911417711">32</xref></sup> We did not stain for nuclear expression of MLH1, PMS2, MSH2, and MSH6 proteins to confirm unaltered mismatch repair genes pathway, linked to either Muir-Torre syndrome or Lynch syndrome, but no internal malignancy in our patient or history of hereditary cancer in the patient’s family was found. Breast cancer (conventional carcinoma) has been also reported in patients affected by Muir-Torre syndrome<sup><xref ref-type="bibr" rid="bibr33-1066896911417711">33</xref><xref ref-type="bibr" rid="bibr34-1066896911417711"/>-<xref ref-type="bibr" rid="bibr35-1066896911417711">35</xref></sup>; however, in our patient no cutaneous sebaceous tumor was detected either in ocularperiorbital sites<sup><xref ref-type="bibr" rid="bibr36-1066896911417711">36</xref></sup> or in extraocular skin locations.<sup><xref ref-type="bibr" rid="bibr30-1066896911417711">30</xref>,<xref ref-type="bibr" rid="bibr31-1066896911417711">31</xref></sup> Regarding the mass in the contralateral right breast, we do not know whether it corresponded to a second primary or to a contralateral breast metastasis: Second contralateral (primary) breast carcinomas, either synchronous or metachronous, are well on record,<sup><xref ref-type="bibr" rid="bibr1-1066896911417711">1</xref>,<xref ref-type="bibr" rid="bibr37-1066896911417711">37</xref>,<xref ref-type="bibr" rid="bibr38-1066896911417711">38</xref></sup> but we do not know if it was metaplastic or more conceivably of a different histotype.</p>
<p>Second, the morphological appearances of the primary tumor were not those of a lipid-rich carcinoma or a variant thereof, which according to WHO classification is defined as “a breast carcinoma in which approximately 90% of neoplastic cells contain abundant cytoplasmic neutral lipid”<sup><xref ref-type="bibr" rid="bibr1-1066896911417711">1</xref></sup> (in this regard we should mention that the first 3 cases of sebaceous tumors of breast<sup><xref ref-type="bibr" rid="bibr26-1066896911417711">26</xref></sup> and the first case of ductal breast carcinomas with sebaceous differentiation<sup><xref ref-type="bibr" rid="bibr16-1066896911417711">16</xref></sup> have been reported as “lipid-rich variants”—however, in accordance with others,<sup><xref ref-type="bibr" rid="bibr17-1066896911417711">17</xref>,<xref ref-type="bibr" rid="bibr23-1066896911417711">23</xref></sup> we have also included these seminal cases in our review in <xref ref-type="table" rid="table3-1066896911417711">Table 3</xref> because of the fact that in both reports these authors subclassified those tumors as “sebaceous type” or “sebaceous-like” lipid-rich breast carcinomas, respectively).</p>
<p>Third, the great majority of metaplastic carcinomas of the breast have a triple-negative and basal-like phenotype<sup><xref ref-type="bibr" rid="bibr39-1066896911417711">39</xref><xref ref-type="bibr" rid="bibr40-1066896911417711"/>-<xref ref-type="bibr" rid="bibr41-1066896911417711">41</xref></sup> with a high frequency rate varying from around 80%<sup><xref ref-type="bibr" rid="bibr42-1066896911417711">42</xref><xref ref-type="bibr" rid="bibr43-1066896911417711"/>-<xref ref-type="bibr" rid="bibr44-1066896911417711">44</xref></sup> to 95%.<sup><xref ref-type="bibr" rid="bibr45-1066896911417711">45</xref></sup> The immunoprofile of the primary tumor in this case was in keeping with the pertinent molecular class of breast cancer as assessed by DNA microarray gene expression profiling studies.<sup><xref ref-type="bibr" rid="bibr46-1066896911417711">46</xref><xref ref-type="bibr" rid="bibr47-1066896911417711"/>-<xref ref-type="bibr" rid="bibr48-1066896911417711">48</xref></sup> With this in mind, the HER-2 positive immunophenotype (ER−, PR−, HER-2+++) of the soft tissue metastasis is especially enigmatic: However, most DNA gene expression profiling studies used primary tumors for analysis and we cannot exclude that similar studies might show different genetic expression in metastases if these secondary tumors are compared with their primaries. Parenthetically, HER2-overexpressing tumors represent the subgroup of breast cancer with the worst outcome.<sup><xref ref-type="bibr" rid="bibr42-1066896911417711">42</xref></sup></p>
<p>Fourth, metaplastic breast carcinoma has an aggressive behavior and a poorer prognosis in comparison with invasive ductal carcinoma, both in general and with specific reference to triple negative ductal carcinomas.<sup>44,49-54</sup> Although the tumor in our case behaved quite aggressively after the patient’s admission, we do not have an actual explanation for the prior 10-year long history implying an originally less aggressive tumor behavior. However, it can be plausibly surmised that the absence of osteochondroid metaplasia played a certain role in this regard. As a matter of fact, in metaplastic breast carcinomas with chondroid differentiation, the aberrant expression of Snail, a transcription factor that downregulates epithelial genes and upregulates mesenchymal genes, results in loss of expression of the cell adhesion molecule E-cadherin in association with changes in epithelial architecture, induction of epithelial mesenchymal transition, changes in invasive growth, and an increase in hematogenous metastatic potential.<sup><xref ref-type="bibr" rid="bibr55-1066896911417711">55</xref>,<xref ref-type="bibr" rid="bibr56-1066896911417711">56</xref></sup> We surmise that osteochondroid metaplasia, as a morphological predictor of poorer prognosis,<sup><xref ref-type="bibr" rid="bibr57-1066896911417711">57</xref>,<xref ref-type="bibr" rid="bibr58-1066896911417711">58</xref></sup> supervened late locally in the primary or even in the soft tissue metastasis, which, considering the large size (17 cm), which was reached at the time of excision, admittedly had to be there for long time. According to our hypothesis, the primary tumor despite being metaplastic carcinoma was of low-intermediate grade (at least initially) as attested to by its lower proliferative fraction index as compared with that of the soft tissue metastatic tumor at the time of its excision (30% vs 80%).</p>
<p>Fifth, although the occurrence of a soft tissue metastasis from a breast cancer is extremely infrequent in general,<sup><xref ref-type="bibr" rid="bibr59-1066896911417711">59</xref>,<xref ref-type="bibr" rid="bibr60-1066896911417711">60</xref></sup> it should be emphasized that in this case the soft tissue lesion was definitely metastatic. Any alternative idea, such as that of a primary mixed soft tissue tumor<sup><xref ref-type="bibr" rid="bibr61-1066896911417711">61</xref>,<xref ref-type="bibr" rid="bibr62-1066896911417711">62</xref></sup> would be fanciful in this clinicopathologic context, and the earlier finding of this most rare type of sebaceous metaplasia in the primary is in favor of the second being a metastasis from the first. Parenthetically, sebaceous metaplasia has never been described in mixed soft tissue tumors<sup><xref ref-type="bibr" rid="bibr61-1066896911417711">61</xref>,<xref ref-type="bibr" rid="bibr62-1066896911417711">62</xref></sup>; nor has it been observed in eccrine mixed tumors of skin,<sup><xref ref-type="bibr" rid="bibr63-1066896911417711">63</xref></sup> whereas it has been seen in mixed tumors of salivary glands,<sup><xref ref-type="bibr" rid="bibr64-1066896911417711">64</xref></sup> and salivary glands are also the most common site of occurrence of sebaceous tumors after the skin.<sup><xref ref-type="bibr" rid="bibr64-1066896911417711">64</xref></sup> Sebaceous differentiation was observed in apocrine mixed tumors of the skin (“mixed tumor of the folliculosebaceous-apocrine complex”), however the tumor presented herein did not show apocrine differentiation either in the primary or in the soft tissue metastasis.<sup><xref ref-type="bibr" rid="bibr65-1066896911417711">65</xref></sup></p>
<p>Sixth, the mixed epithelial and mesenchymal aspect of this soft tissue metastasis is of the greatest interest. The phenotypic transition from the purely epithelial morphology of the primary to the mixed (epithelial and osteochondroid) phenotype of the metastasis could have supervened at an invasive late stage of the primary (assuming a small focus of mesenchymal differentiation escaped pathological sampling) or only at the metastatic site. Specific genetic hits occur at various stages of carcinogenesis as demonstrated using in vivo clinical data<sup><xref ref-type="bibr" rid="bibr9-1066896911417711">9</xref>,<xref ref-type="bibr" rid="bibr66-1066896911417711">66</xref></sup> or in analyzing molecularly microdissected diverse components of metaplastic carcinomas: The latter studies showed submodal clones of cancer cells with similar genetic profiles, attesting to the same initiating genetic lesion for distinct components of this tumor.<sup><xref ref-type="bibr" rid="bibr67-1066896911417711">67</xref></sup></p>
<p>Last, also of interest are some of the immunohistochemical findings we observed in the primary tumor reported herein, that is, the foci of α-smooth muscle actin positive neoplastic spindle cells, likely indicating early myoepithelial differentiation, which is a possible occurrence<sup><xref ref-type="bibr" rid="bibr6-1066896911417711">6</xref></sup> that is also molecularly supported<sup><xref ref-type="bibr" rid="bibr45-1066896911417711">45</xref></sup>; the immunopositivity of the ductal adenocarcinomatous component for HMW-CK as well as its p63 negativity (this latter finding already seen in a large series of such tumors by other investigators<sup><xref ref-type="bibr" rid="bibr68-1066896911417711">68</xref></sup>); the GCDFP-15 negativity, attesting to the lack of apocrine differentiation; the CEA negativity as previously documented also by others,<sup><xref ref-type="bibr" rid="bibr17-1066896911417711">17</xref>,<xref ref-type="bibr" rid="bibr22-1066896911417711">22</xref>,<xref ref-type="bibr" rid="bibr23-1066896911417711">23</xref></sup> which is well in accordance with the breast origin of our tumor (in any case and for completeness sake we should say that in 1 case of pure sebaceous carcinoma, CEA was positive in the clear foamy sebaceous cells and negative in the basal-type dark sebaceous cells<sup><xref ref-type="bibr" rid="bibr24-1066896911417711">24</xref></sup>); the EMA positivity of the sebaceous cells as previously demonstrated by Prescott et al<sup><xref ref-type="bibr" rid="bibr22-1066896911417711">22</xref></sup> and Murakami et al<sup><xref ref-type="bibr" rid="bibr24-1066896911417711">24</xref></sup> in their own cases (even though in 1 case of pure sebaceous carcinoma of the breast EMA was negative<sup><xref ref-type="bibr" rid="bibr23-1066896911417711">23</xref></sup>); and finally, the AR negativity, despite the reputation this hormone receptor has as a sensitive marker of sebaceous differentiation in both normal sebaceous cells and sebaceous neoplasms of the skin<sup><xref ref-type="bibr" rid="bibr69-1066896911417711">69</xref>,<xref ref-type="bibr" rid="bibr70-1066896911417711">70</xref></sup> (AR has been tested in 4 previous cases of sebaceous carcinomas of the breast, 1 of which was positive<sup><xref ref-type="bibr" rid="bibr24-1066896911417711">24</xref></sup> and 3 negative<sup><xref ref-type="bibr" rid="bibr12-1066896911417711">12</xref>,<xref ref-type="bibr" rid="bibr17-1066896911417711">17</xref>,<xref ref-type="bibr" rid="bibr23-1066896911417711">23</xref></sup>).</p>
<p>In summary, we report a unique case of metaplastic carcinoma of the breast with dominant squamous and sebaceous differentiation in the primary and osteochondroid metaplasia in a distant metastasis, whose immunoprofile switched from triple negative in the primary to HER-2 positive in the metastasis.</p>
</sec>
</body>
<back>
<ack><p>Dr Juan Rosai (Centro Diagnostico Italiano, International Center for Oncologic Pathology Consultations, Milan, Italy) is gratefully acknowledged for having examined the microscopic sections of the case, for reading the article, and for discussing with the corresponding author the histogenetic and pathogenetic considerations raised by this tumor.</p></ack>
<fn-group>
<fn fn-type="conflict">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1066896911417711">
<label>1.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Ellis</surname><given-names>IO</given-names></name>
<name><surname>Schnitt</surname><given-names>SJ</given-names></name>
<name><surname>Sastre-Garau</surname><given-names>X</given-names></name>
<etal/>
</person-group>. <article-title>Invasive breast carcinoma</article-title>. In: <person-group person-group-type="editor">
<name><surname>Tavassoli</surname><given-names>FA</given-names></name>
<name><surname>Devilee</surname><given-names>P</given-names></name>
</person-group>, eds. <source>World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs</source>. <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC Press</publisher-name>; <volume>2003</volume>:<fpage>13</fpage>-<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr2-1066896911417711">
<label>2.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Bisceglia</surname><given-names>M</given-names></name>
<name><surname>Magro</surname><given-names>G</given-names></name>
<name><surname>Lamovec</surname><given-names>J</given-names></name>
<name><surname>Mantovani</surname><given-names>W</given-names></name>
<name><surname>Pasquinelli</surname><given-names>G</given-names></name>
</person-group>. <article-title>Carcinoma metaplastico o sarcomatoide (e sottotipi)</article-title>. In: <source>Gli istotipi speciali del carcinoma duttale invasivo della mammella: inquadramento clinico-patologico, microscopico e ultrastrutturale</source>. <publisher-loc>Ospedaletto-Pisa, Pacini Editore</publisher-loc>: <volume>2001</volume>:<fpage>44</fpage>-<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr3-1066896911417711">
<label>3.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Tavassoli</surname><given-names>FA</given-names></name>
<name><surname>Eusebi</surname><given-names>V</given-names></name>
</person-group>. <article-title>Uncommon variants of carcinoma</article-title>. In: <source>Tumors of the Mammary Gland. AFIP Atlas Tumor of Pathology</source>. <series>Series 4</series>. <comment>Fascicle 10</comment>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Registry of Pathology, Armed Forces Institute of Pathology</publisher-name>; <volume>2009</volume>:<fpage>217</fpage>-<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr4-1066896911417711">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurian</surname><given-names>KM</given-names></name>
<name><surname>Al-Nafussi</surname><given-names>A</given-names></name>
</person-group>. <article-title>Sarcomatoid/metaplastic carcinoma of the breast: a clinicopathological study of 12 cases</article-title>. <source>Histopathology</source>. <year>2002</year>;<volume>40</volume>:<fpage>58</fpage>-<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr5-1066896911417711">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sneige</surname><given-names>N</given-names></name>
<name><surname>Yaziji</surname><given-names>H</given-names></name>
<name><surname>Mandavilli</surname><given-names>SR</given-names></name>
<etal/>
</person-group>. <article-title>Low-grade (fibromatosis-like) spindle cell carcinoma of the breast</article-title>. <source>Am J Surg Pathol</source>. <year>2001</year>;<volume>25</volume>:<fpage>1009</fpage>-<lpage>1016</lpage>.</citation>
</ref>
<ref id="bibr6-1066896911417711">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carter</surname><given-names>MR</given-names></name>
<name><surname>Hornick</surname><given-names>JL</given-names></name>
<name><surname>Lester</surname><given-names>S</given-names></name>
<name><surname>Fletcher</surname><given-names>CD</given-names></name>
</person-group>. <article-title>Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases</article-title>. <source>Am J Surg Pathol</source>. <year>2006</year>;<volume>30</volume>:<fpage>300</fpage>-<lpage>309</lpage>.</citation>
</ref>
<ref id="bibr7-1066896911417711">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santeusanio</surname><given-names>G</given-names></name>
<name><surname>Pascal</surname><given-names>RR</given-names></name>
<name><surname>Bisceglia</surname><given-names>M</given-names></name>
<name><surname>Costantino</surname><given-names>AM</given-names></name>
<name><surname>Bosman</surname><given-names>C</given-names></name>
</person-group>. <article-title>Metaplastic breast carcinoma with epithelial phenotype of pseudosarcomatous components</article-title>. <source>Arch Pathol Lab Med</source>. <year>1988</year>;<volume>112</volume>:<fpage>82</fpage>-<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr8-1066896911417711">
<label>8.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Schnitt</surname><given-names>SJ</given-names></name>
<name><surname>Collins</surname><given-names>LC</given-names></name>
</person-group>. <source>Biopsy Interpretation of the Breast</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>; <year>2009</year>; <fpage>249</fpage>-<lpage>322</lpage>.</citation>
</ref>
<ref id="bibr9-1066896911417711">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van Deurzen</surname><given-names>CH</given-names></name>
<name><surname>Lee</surname><given-names>AH</given-names></name>
<name><surname>Gill</surname><given-names>MS</given-names></name>
<etal/>
</person-group>. <article-title>Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation?</article-title> <source>J Pathol</source>. <year>2011</year>;<volume>224</volume>:<fpage>434</fpage>-<lpage>437</lpage>.</citation>
</ref>
<ref id="bibr10-1066896911417711">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lien</surname><given-names>HC</given-names></name>
<name><surname>Hsiao</surname><given-names>YH</given-names></name>
<name><surname>Lin</surname><given-names>YS</given-names></name>
<etal/>
</person-group>. <article-title>Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition</article-title>. <source>Oncogene</source>. <year>2007</year>;<volume>26</volume>: <fpage>7859</fpage>-<lpage>7871</lpage>.</citation>
</ref>
<ref id="bibr11-1066896911417711">
<label>11.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Rosen</surname><given-names>PP</given-names></name>
</person-group>. <source>Rosen’s Breast Pathology</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>; <year>2009</year>; <fpage>470</fpage>-<lpage>506</lpage>.</citation>
</ref>
<ref id="bibr12-1066896911417711">
<label>12.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Tavassoli</surname><given-names>FA</given-names></name>
</person-group>. <source>Pathology of the Breast</source>. <edition>2nd ed.</edition> <publisher-loc>Stamford, CT</publisher-loc>: <publisher-name>Appleton &amp; Lange</publisher-name>; <year>1999</year>; <comment>(a): 481-504; (b): 555-558</comment>.</citation>
</ref>
<ref id="bibr13-1066896911417711">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jamieson</surname><given-names>S</given-names></name>
<name><surname>Rudland</surname><given-names>PS</given-names></name>
</person-group>. <article-title>Identification of metaplastic variants generated by transfection of a nonmetastatic rat mammary epithelial cell line with DNA from a metastatic rat mammary cell line</article-title>. <source>Am J Pathol</source>. <year>1990</year>;<volume>137</volume>:<fpage>629</fpage>-<lpage>641</lpage>.</citation>
</ref>
<ref id="bibr14-1066896911417711">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tavassoli</surname><given-names>FA</given-names></name>
<name><surname>Norris</surname><given-names>HJ</given-names></name>
</person-group>. <article-title>Mammary adenoid cystic carcinoma with sebaceous differentiation. A morphologic study of the cell types</article-title>. <source>Arch Pathol Lab Med</source>. <year>1986</year>;<volume>110</volume>: <fpage>1045</fpage>-<lpage>1053</lpage>.</citation>
</ref>
<ref id="bibr15-1066896911417711">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kinkor</surname><given-names>Z</given-names></name>
<name><surname>Meciarová</surname><given-names>I</given-names></name>
<name><surname>Havlícek</surname><given-names>F</given-names></name>
</person-group>. <article-title>Primary sebaceous carcinoma of the breast: three casuistic reports [in Czech]</article-title>. <source>Ceska Gynekol</source>. <year>2010</year>;<volume>75</volume>:<fpage>50</fpage>-<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr16-1066896911417711">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mazzella</surname><given-names>FM</given-names></name>
<name><surname>Sieber</surname><given-names>SC</given-names></name>
<name><surname>Braza</surname><given-names>F</given-names></name>
</person-group>. <article-title>Ductal carcinoma of male breast with prominent lipid-rich component</article-title>. <source>Pathology</source>. <year>1995</year>; <volume>27</volume>:<fpage>280</fpage>-<lpage>283</lpage>.</citation>
</ref>
<ref id="bibr17-1066896911417711">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Varga</surname><given-names>Z</given-names></name>
<name><surname>Kolb</surname><given-names>SA</given-names></name>
<name><surname>Flury</surname><given-names>R</given-names></name>
<name><surname>Burkhard</surname><given-names>R</given-names></name>
<name><surname>Caduff</surname><given-names>R</given-names></name>
</person-group>. <article-title>Sebaceous carcinoma of the breast</article-title>. <source>Pathol Int</source>. <year>2000</year>;<volume>50</volume>: <fpage>63</fpage>-<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr18-1066896911417711">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cai</surname><given-names>RZ</given-names></name>
<name><surname>Tan</surname><given-names>PH</given-names></name>
</person-group>. <article-title>Adenomyoepithelioma of the breast with squamous and sebaceous metaplasia</article-title>. <source>Pathology</source>. <year>2005</year>;<volume>37</volume>: <fpage>557</fpage>-<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr19-1066896911417711">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tavassoli</surname><given-names>FA</given-names></name>
</person-group>. <article-title>Myoepithelial lesions of the breast. Myoepitheliosis, adenomyoepithelioma, and myoepithelial carcinoma</article-title>. <source>Am J Surg Pathol</source>. <year>1991</year>;<volume>15</volume>:<fpage>554</fpage>-<lpage>568</lpage>.</citation>
</ref>
<ref id="bibr20-1066896911417711">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gao</surname><given-names>HW</given-names></name>
<name><surname>Wu</surname><given-names>Y</given-names></name>
<name><surname>Yao</surname><given-names>M</given-names></name>
<name><surname>Chen</surname><given-names>SF</given-names></name>
<name><surname>Xu</surname><given-names>CJ</given-names></name>
</person-group>. <article-title>Intraduct papilloma of breast with sebaceous metaplasia: report of a case [in CHinese]</article-title>. <source>Zhonghua Bing Li Xue Za Zhi</source>. <year>2007</year>;<volume>36</volume>:<fpage>349</fpage>-<lpage>350</lpage>.</citation>
</ref>
<ref id="bibr21-1066896911417711">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jiao</surname><given-names>Y-F</given-names></name>
<name><surname>Nakamura</surname><given-names>S</given-names></name>
<name><surname>Oikawa</surname><given-names>T</given-names></name>
<name><surname>Sugai</surname><given-names>T</given-names></name>
<name><surname>Uesugi</surname><given-names>N</given-names></name>
</person-group>. <article-title>Sebaceous gland metaplasia in intraductal papilloma of the breast</article-title>. <source>Virchows Arch</source>.<year>2001</year>;<volume>438</volume>:<fpage>505</fpage>-<lpage>508</lpage>.</citation>
</ref>
<ref id="bibr22-1066896911417711">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prescott</surname><given-names>RJ</given-names></name>
<name><surname>Eyden</surname><given-names>BP</given-names></name>
<name><surname>Reeve</surname><given-names>NL</given-names></name>
</person-group>. <article-title>Sebaceous differentiation in a breast carcinoma with ductal, myoepithelial and squamous elements</article-title>. <source>Histopathology</source>. <year>1992</year>;<volume>21</volume>:<fpage>181</fpage>-<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr23-1066896911417711">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hisaoka</surname><given-names>M</given-names></name>
<name><surname>Takamatsu</surname><given-names>Y</given-names></name>
<name><surname>Hirano</surname><given-names>Y</given-names></name>
<name><surname>Maeda</surname><given-names>H</given-names></name>
<name><surname>Hamada</surname><given-names>T</given-names></name>
</person-group>. <article-title>Sebaceous carcinoma of the breast: case report and review of the literature</article-title>. <source>Virchows Arch</source>. <year>2006</year>;<volume>449</volume>:<fpage>484</fpage>-<lpage>488</lpage>.</citation>
</ref>
<ref id="bibr24-1066896911417711">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murakami</surname><given-names>A</given-names></name>
<name><surname>Kawachi</surname><given-names>K</given-names></name>
<name><surname>Sasaki</surname><given-names>T</given-names></name>
<name><surname>Ishikawa</surname><given-names>T</given-names></name>
<name><surname>Nagashima</surname><given-names>Y</given-names></name>
<name><surname>Nozawa</surname><given-names>A</given-names></name>
</person-group>. <article-title>Sebaceous carcinoma of the breast</article-title>. <source>Pathol Int</source>. <year>2009</year>;<volume>59</volume>:<fpage>188</fpage>-<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr25-1066896911417711">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramljak</surname><given-names>V</given-names></name>
<name><surname>Sarcević</surname><given-names>B</given-names></name>
<name><surname>Vrdoljak</surname><given-names>DV</given-names></name>
<name><surname>Kelcec</surname><given-names>IB</given-names></name>
<name><surname>Agai</surname><given-names>M</given-names></name>
<name><surname>Ostović</surname><given-names>KT</given-names></name>
</person-group>. <article-title>Fine needle aspiration cytology in diagnosing rare breast carcinoma: two case reports</article-title>. <source>Coll Antropol</source>. <year>2010</year>;<volume>34</volume>:<fpage>201</fpage>-<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr26-1066896911417711">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van Bogaert</surname><given-names>LJ</given-names></name>
<name><surname>Maldague</surname><given-names>P</given-names></name>
</person-group>. <article-title>Histologic variants of lipid secreting carcinoma of the breast</article-title>. <source>Virchows Arch Pathol Anat</source>. <year>1977</year>;<volume>375</volume>:<fpage>345</fpage>-<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr27-1066896911417711">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alzaraa</surname><given-names>A</given-names></name>
<name><surname>Ghafoor</surname><given-names>I</given-names></name>
<name><surname>Yates</surname><given-names>A</given-names></name>
<name><surname>Dhebri</surname><given-names>A</given-names></name>
</person-group>. <article-title>Sebaceous carcinoma of the skin of the breast: a case report</article-title>. <source>J Med Case Reports</source>. <year>2008</year>;<volume>2</volume>:<fpage>276</fpage>.</citation>
</ref>
<ref id="bibr28-1066896911417711">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cibull</surname><given-names>TL</given-names></name>
<name><surname>Thomas</surname><given-names>AB</given-names></name>
<name><surname>Badve</surname><given-names>S</given-names></name>
<name><surname>Billings</surname><given-names>SD</given-names></name>
</person-group>. <article-title>Sebaceous carcinoma of the nipple</article-title>. <source>J Cutan Pathol</source>. <year>2008</year>;<volume>35</volume>:<fpage>608</fpage>-<lpage>610</lpage>.</citation>
</ref>
<ref id="bibr29-1066896911417711">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Propeck</surname><given-names>PA</given-names></name>
<name><surname>Warner</surname><given-names>T</given-names></name>
<name><surname>Scanlan</surname><given-names>KA</given-names></name>
</person-group>. <article-title>Sebaceous carcinoma of the breast in a patient with Muir-Torre syndrome</article-title>. <source>AJR Am J Roentgenol</source>. <year>2000</year>;<volume>174</volume>:<fpage>541</fpage>-<lpage>542</lpage>.</citation>
</ref>
<ref id="bibr30-1066896911417711">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>P</given-names></name>
<name><surname>Kohn</surname><given-names>S</given-names></name>
<name><surname>Davis</surname><given-names>D</given-names></name>
<name><surname>Kurzrock</surname><given-names>R</given-names></name>
</person-group>. <article-title>Muir-Torre syndrome</article-title>. <source>Dermatol Clin</source>. <year>1995</year>;<volume>13</volume>:<fpage>79</fpage>-<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr31-1066896911417711">
<label>31.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Rütten</surname><given-names>Wick MR</given-names></name>
<name><surname>Sangüeza</surname><given-names>Wallace C</given-names></name>
</person-group>. <article-title>Tumors with sebaceous differentiation</article-title>. In: <person-group person-group-type="editor">
<name><surname>LeBoit</surname><given-names>PE</given-names></name>
<name><surname>Burg</surname><given-names>G</given-names></name>
<name><surname>Weedon</surname><given-names>D</given-names></name>
<name><surname>Sarasain</surname><given-names>A</given-names></name>
</person-group>, eds. <source>World Health Organization Classification of Tumors. Pathology and Genetics of Skin Tumours</source>. <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC Press</publisher-name>; <volume>2006</volume>:<fpage>160</fpage>-<lpage>163</lpage>.</citation>
</ref>
<ref id="bibr32-1066896911417711">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kruse</surname><given-names>R</given-names></name>
<name><surname>Rütten</surname><given-names>A</given-names></name>
<name><surname>Lamberti</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria</article-title>. <source>Am J Hum Genet</source>. <year>1998</year>;<volume>63</volume>:<fpage>63</fpage>-<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr33-1066896911417711">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Finan</surname><given-names>MC</given-names></name>
<name><surname>Connolly</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Sebaceous gland tumors and systemic disease: a clinicopathologic analysis</article-title>. <source>Medicine (Baltimore)</source>. <year>1984</year>;<volume>63</volume>:<fpage>232</fpage>-<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr34-1066896911417711">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Graham</surname><given-names>R</given-names></name>
<name><surname>McKee</surname><given-names>P</given-names></name>
<name><surname>McGibbon</surname><given-names>D</given-names></name>
<name><surname>Heyderman</surname><given-names>E</given-names></name>
</person-group>. <article-title>Torre-Muir syndrome. An association with isolated sebaceous carcinoma</article-title>. <source>Cancer</source>. <year>1985</year>;<volume>55</volume>:<fpage>2868</fpage>-<lpage>2873</lpage>.</citation>
</ref>
<ref id="bibr35-1066896911417711">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newman</surname><given-names>BD</given-names></name>
<name><surname>Maher</surname><given-names>JF</given-names></name>
<name><surname>Subauste</surname><given-names>JS</given-names></name>
<name><surname>Uwaifo</surname><given-names>GI</given-names></name>
<name><surname>Bigler</surname><given-names>SA</given-names></name>
<name><surname>Koch</surname><given-names>CA</given-names></name>
</person-group>. <article-title>Clustering of sebaceous gland carcinoma, papillary thyroid carcinoma and breast cancer in a woman as a new cancer susceptibility disorder: a case report</article-title>. <source>J Med Case Reports</source>. <year>2009</year>;<volume>3</volume>:<fpage>6905</fpage>.</citation>
</ref>
<ref id="bibr36-1066896911417711">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rao</surname><given-names>NA</given-names></name>
<name><surname>Hidayat</surname><given-names>AA</given-names></name>
<name><surname>McLean</surname><given-names>IW</given-names></name>
<name><surname>Zimmerman</surname><given-names>LE</given-names></name>
</person-group>. <article-title>Sebaceous carcinomas of the ocular adnexa: a clinicopathologic study of 104 cases, with five-year follow-up data</article-title>. <source>Hum Pathol</source>. <year>1982</year>;<volume>13</volume>:<fpage>113</fpage>-<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr37-1066896911417711">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chaudery</surname><given-names>MA</given-names></name>
<name><surname>Mills</surname><given-names>RR</given-names></name>
<name><surname>Hoskins</surname><given-names>EOL</given-names></name>
<etal/>
</person-group>. <article-title>Bilateral breast cancer: a prospective study of disease incidence</article-title>. <source>Br J Surg</source>. <year>1984</year>;<volume>71</volume>:<fpage>711</fpage>-<lpage>714</lpage>.</citation>
</ref>
<ref id="bibr38-1066896911417711">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Donovan</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>Bilateral breast cancer</article-title>. <source>Surg Clin North Am</source>. <year>1990</year>;<volume>70</volume>:<fpage>1141</fpage>-<lpage>1149</lpage>.</citation>
</ref>
<ref id="bibr39-1066896911417711">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Demir</surname><given-names>H</given-names></name>
<name><surname>Turna</surname><given-names>H</given-names></name>
<name><surname>Can</surname><given-names>G</given-names></name>
<name><surname>Ilvan</surname><given-names>S</given-names></name>
</person-group>. <article-title>Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression</article-title>. <source>J BUON</source>. <year>2010</year>;<volume>15</volume>:<fpage>774</fpage>-<lpage>782</lpage>.</citation>
</ref>
<ref id="bibr40-1066896911417711">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gauchotte</surname><given-names>G</given-names></name>
<name><surname>Gauchotte</surname><given-names>E</given-names></name>
<name><surname>Bressenot</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Metaplastic carcinomas of the breast: a morphological and immunohistochemical study [in French]</article-title>. <source>Ann Pathol</source>. <year>2011</year>;<volume>31</volume>:<fpage>18</fpage>-<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr41-1066896911417711">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iwase</surname><given-names>H</given-names></name>
<name><surname>Kurebayashi</surname><given-names>J</given-names></name>
<name><surname>Tsuda</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society</article-title>. <source>Breast Cancer</source>. <year>2010</year>;<volume>17</volume>:<fpage>118</fpage>-<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr42-1066896911417711">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>MJ</given-names></name>
<name><surname>Ro</surname><given-names>JY</given-names></name>
<name><surname>Ahn</surname><given-names>SH</given-names></name>
<name><surname>Kim</surname><given-names>HH</given-names></name>
<name><surname>Kim</surname><given-names>SB</given-names></name>
<name><surname>Gong</surname><given-names>G</given-names></name>
</person-group>. <article-title>Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes</article-title>. <source>Hum Pathol</source>. <year>2006</year>;<volume>37</volume>: <fpage>1217</fpage>-<lpage>1226</lpage>.</citation>
</ref>
<ref id="bibr43-1066896911417711">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lim</surname><given-names>KH</given-names></name>
<name><surname>Oh</surname><given-names>DY</given-names></name>
<name><surname>Chie</surname><given-names>EK</given-names></name>
<etal/>
</person-group>. <article-title>Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity</article-title>. <source>Jpn J Clin Oncol</source>. <year>2010</year>;<volume>40</volume>:<fpage>112</fpage>-<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr44-1066896911417711">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>HS</given-names></name>
<name><surname>Park</surname><given-names>S</given-names></name>
<name><surname>Kim</surname><given-names>JH</given-names></name>
<etal/>
</person-group>. <article-title>Clinicopathologic features and outcomes of metaplastic breast carcinoma: comparison with invasive ductal carcinoma of the breast</article-title>. <source>Yonsei Med J</source>. <year>2010</year>;<volume>51</volume>:<fpage>864</fpage>-<lpage>869</lpage>.</citation>
</ref>
<ref id="bibr45-1066896911417711">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weigelt</surname><given-names>B</given-names></name>
<name><surname>Kreike</surname><given-names>B</given-names></name>
<name><surname>Reis-Filho</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis</article-title>. <source>Breast Cancer Res Treat</source>. <year>2009</year>;<volume>117</volume>:<fpage>273</fpage>-<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr46-1066896911417711">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perou</surname><given-names>CM</given-names></name>
<name><surname>Sørlie</surname><given-names>T</given-names></name>
<name><surname>Eisen</surname><given-names>MB</given-names></name>
<etal/>
</person-group>. <article-title>Molecular portraits of human breast tumours</article-title>. <source>Nature</source>. <year>2000</year>;<volume>406</volume>:<fpage>747</fpage>-<lpage>752</lpage>.</citation>
</ref>
<ref id="bibr47-1066896911417711">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sorlie</surname><given-names>T</given-names></name>
<name><surname>Perou</surname><given-names>CM</given-names></name>
<name><surname>Tibshirani</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2001</year>;<volume>98</volume>: <fpage>10869</fpage>-<lpage>10874</lpage>.</citation>
</ref>
<ref id="bibr48-1066896911417711">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weigelt</surname><given-names>B</given-names></name>
<name><surname>Horlings</surname><given-names>HM</given-names></name>
<name><surname>Kreike</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Refinement of breast cancer classification by molecular characterization of histological special types</article-title>. <source>J Pathol</source>. <year>2008</year>;<volume>216</volume>:<fpage>141</fpage>-<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr49-1066896911417711">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bae</surname><given-names>SY</given-names></name>
<name><surname>Lee</surname><given-names>SK</given-names></name>
<name><surname>Koo</surname><given-names>MY</given-names></name>
<etal/>
</person-group>. <article-title>The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients</article-title>. <source>Breast Cancer Res Treat</source>. <year>2011</year>;<volume>126</volume>:<fpage>471</fpage>-<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr50-1066896911417711">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beatty</surname><given-names>JD</given-names></name>
<name><surname>Atwood</surname><given-names>M</given-names></name>
<name><surname>Tickman</surname><given-names>R</given-names></name>
<name><surname>Reiner</surname><given-names>M</given-names></name>
</person-group>. <article-title>Metaplastic breast cancer: clinical significance</article-title>. <source>Am J Surg</source>. <year>2006</year>;<volume>191</volume>:<fpage>657</fpage>-<lpage>664</lpage>.</citation>
</ref>
<ref id="bibr51-1066896911417711">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jung</surname><given-names>SY</given-names></name>
<name><surname>Kim</surname><given-names>HY</given-names></name>
<name><surname>Nam</surname><given-names>BH</given-names></name>
<etal/>
</person-group>. <article-title>Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer</article-title>. <source>Breast Cancer Res Treat</source>. <year>2010</year>;<volume>120</volume>: <fpage>627</fpage>-<lpage>637</lpage>.</citation>
</ref>
<ref id="bibr52-1066896911417711">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luini</surname><given-names>A</given-names></name>
<name><surname>Aguilar</surname><given-names>M</given-names></name>
<name><surname>Gatti</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature</article-title>. <source>Breast Cancer Res Treat</source>. <year>2007</year>;<volume>101</volume>:<fpage>349</fpage>-<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr53-1066896911417711">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Okada</surname><given-names>N</given-names></name>
<name><surname>Hasebe</surname><given-names>T</given-names></name>
<name><surname>Iwasaki</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Metaplastic carcinoma of the breast</article-title>. <source>Hum Pathol</source>. <year>2010</year>;<volume>41</volume>:<fpage>960</fpage>-<lpage>970</lpage>.</citation>
</ref>
<ref id="bibr54-1066896911417711">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamaguchi</surname><given-names>R</given-names></name>
<name><surname>Horii</surname><given-names>R</given-names></name>
<name><surname>Maeda</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>Clinicopathologic study of 53 metaplastic breast carcinomas: their elements and prognostic implications</article-title>. <source>Hum Pathol</source>. <year>2010</year>;<volume>41</volume>:<fpage>679</fpage>-<lpage>685</lpage>.</citation>
</ref>
<ref id="bibr55-1066896911417711">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gwin</surname><given-names>K</given-names></name>
<name><surname>Buell-Gutbrod</surname><given-names>R</given-names></name>
<name><surname>Tretiakova</surname><given-names>M</given-names></name>
<name><surname>Montag</surname><given-names>A</given-names></name>
</person-group>. <article-title>Epithelial-to-mesenchymal transition in metaplastic breast carcinomas with chondroid differentiation: expression of the E-cadherin repressor Snail</article-title>. <source>Appl Immunohistochem Mol Morphol</source>. <year>2010</year>;<volume>18</volume>:<fpage>526</fpage>-<lpage>531</lpage>.</citation>
</ref>
<ref id="bibr56-1066896911417711">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nassar</surname><given-names>A</given-names></name>
<name><surname>Sookhan</surname><given-names>N</given-names></name>
<name><surname>Santisteban</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Diagnostic utility of snail in metaplastic breast carcinoma</article-title>. <source>Diagn Pathol</source>. <year>2010</year>;<volume>5</volume>:<fpage>76</fpage>.</citation>
</ref>
<ref id="bibr57-1066896911417711">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Downs-Kelly</surname><given-names>E</given-names></name>
<name><surname>Nayeemuddin</surname><given-names>KM</given-names></name>
<name><surname>Albarracin</surname><given-names>C</given-names></name>
<name><surname>Wu</surname><given-names>Y</given-names></name>
<name><surname>Hunt</surname><given-names>KK</given-names></name>
<name><surname>Gilcrease</surname><given-names>MZ</given-names></name>
</person-group>. <article-title>Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma</article-title>. <source>Am J Surg Pathol</source>. <year>2009</year>;<volume>33</volume>:<fpage>534</fpage>-<lpage>541</lpage>.</citation>
</ref>
<ref id="bibr58-1066896911417711">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gwin</surname><given-names>K</given-names></name>
<name><surname>Wheeler</surname><given-names>DT</given-names></name>
<name><surname>Bossuyt</surname><given-names>V</given-names></name>
<name><surname>Tavassoli</surname><given-names>FA</given-names></name>
</person-group>. <article-title>Breast carcinoma with chondroid differentiation: a clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases</article-title>. <source>Int J Surg Pathol</source>. <year>2010</year>;<volume>18</volume>:<fpage>27</fpage>-<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr59-1066896911417711">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abed</surname><given-names>R</given-names></name>
<name><surname>Grimer</surname><given-names>RJ</given-names></name>
<name><surname>Carter</surname><given-names>SR</given-names></name>
<name><surname>Tillman</surname><given-names>RM</given-names></name>
<name><surname>Abudu</surname><given-names>A</given-names></name>
<name><surname>Jeys</surname><given-names>L</given-names></name>
</person-group>. <article-title>Soft-tissue metastases: their presentation and origin</article-title>. <source>J Bone Joint Surg Br</source>. <year>2009</year>;<volume>91</volume>:<fpage>1083</fpage>-<lpage>1085</lpage>.</citation>
</ref>
<ref id="bibr60-1066896911417711">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Plaza</surname><given-names>JA</given-names></name>
<name><surname>Perez-Montiel</surname><given-names>D</given-names></name>
<name><surname>Mayerson</surname><given-names>J</given-names></name>
<name><surname>Morrison</surname><given-names>C</given-names></name>
<name><surname>Suster</surname><given-names>S</given-names></name>
</person-group>. <article-title>Metastases to soft tissue: a review of 118 cases over a 30-year period</article-title>. <source>Cancer</source>. <year>2008</year>;<volume>112</volume>:<fpage>193</fpage>-<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr61-1066896911417711">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bisceglia</surname><given-names>M</given-names></name>
<name><surname>Fisher</surname><given-names>C</given-names></name>
<name><surname>Suster</surname><given-names>S</given-names></name>
<name><surname>Kazakov</surname><given-names>DV</given-names></name>
<name><surname>Cooper</surname><given-names>K</given-names></name>
<name><surname>Michal</surname><given-names>M</given-names></name>
</person-group>. <article-title>Tumoral, quasitumoral and pseudotumoral lesions of the superficial and somatic soft tissue: new entities and new variants of old entities recorded during the last 25 years. Part IX: excerpta VII</article-title>. <source>Pathologica</source>. <year>2005</year>;<volume>97</volume>: <fpage>343</fpage>-<lpage>360</lpage>.</citation>
</ref>
<ref id="bibr62-1066896911417711">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kilpatrick</surname><given-names>SE</given-names></name>
<name><surname>Hitchcock</surname><given-names>MG</given-names></name>
<name><surname>Kraus</surname><given-names>MD</given-names></name>
<name><surname>Calonje</surname><given-names>E</given-names></name>
<name><surname>Fletcher</surname><given-names>CD</given-names></name>
</person-group>. <article-title>Mixed tumors and myoepitheliomas of soft tissue: a clinicopathologic study of 19 cases with a unifying concept</article-title>. <source>Am J Surg Pathol</source>. <year>1997</year>;<volume>21</volume>:<fpage>13</fpage>-<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr63-1066896911417711">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kazakov</surname><given-names>DV</given-names></name>
<name><surname>Kacerovska</surname><given-names>D</given-names></name>
<name><surname>Hantschke</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Cutaneous mixed tumor, eccrine variant: a clinicopathologic and immunohistochemical study of 50 cases, with emphasis on unusual histopathologic features</article-title>. <source>Am J Dermatopathol</source>. <year>2011</year>;<volume>33</volume>:<fpage>557</fpage>-<lpage>568</lpage>.</citation>
</ref>
<ref id="bibr64-1066896911417711">
<label>64.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Ellis</surname><given-names>GL</given-names></name>
<name><surname>Auclair</surname><given-names>PL</given-names></name>
</person-group>. <article-title>Benign epithelial neoplasms</article-title>. <source>Atlas of Tumor Pathology. Tumors of the Salivary Glands</source>. <series>3rd Series</series>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>Armed Forces Institute of Pathology</publisher-name>; <volume>1996</volume>:<fpage>39</fpage>-<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr65-1066896911417711">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kazakov</surname><given-names>DV</given-names></name>
<name><surname>Belousova</surname><given-names>IE</given-names></name>
<name><surname>Bisceglia</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Apocrine mixed tumor of the skin (“mixed tumor of the folliculosebaceous-apocrine complex”). Spectrum of differentiations and metaplastic changes in the epithelial, myoepithelial, and stromal components based on a histopathologic study of 244 cases</article-title>. <source>J Am Acad Dermatol</source>. <year>2007</year>;<volume>57</volume>:<fpage>467</fpage>-<lpage>483</lpage>.</citation>
</ref>
<ref id="bibr66-1066896911417711">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Osako</surname><given-names>T</given-names></name>
<name><surname>Horii</surname><given-names>R</given-names></name>
<name><surname>Ogiya</surname><given-names>A</given-names></name>
<name><surname>Iijima</surname><given-names>K</given-names></name>
<name><surname>Iwase</surname><given-names>T</given-names></name>
<name><surname>Akiyama</surname><given-names>F</given-names></name>
</person-group>. <article-title>Histogenesis of metaplastic breast carcinoma and axillary nodal metastases</article-title>. <source>Pathol Int</source>. <year>2009</year>;<volume>59</volume>:<fpage>116</fpage>-<lpage>120</lpage>.</citation>
</ref>
<ref id="bibr67-1066896911417711">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geyer</surname><given-names>FC</given-names></name>
<name><surname>Weigelt</surname><given-names>B</given-names></name>
<name><surname>Natrajan</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas</article-title>. <source>J Pathol</source>. <year>2010</year>;<volume>220</volume>: <fpage>562</fpage>-<lpage>573</lpage>.</citation>
</ref>
<ref id="bibr68-1066896911417711">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tse</surname><given-names>GM</given-names></name>
<name><surname>Tan</surname><given-names>PH</given-names></name>
<name><surname>Chaiwun</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>p63 is useful in the diagnosis of mammary metaplastic carcinomas</article-title>. <source>Pathology</source>. <year>2006</year>;<volume>38</volume>:<fpage>16</fpage>-<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr69-1066896911417711">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bayer-Garner</surname><given-names>IB</given-names></name>
<name><surname>Givens</surname><given-names>V</given-names></name>
<name><surname>Smoller</surname><given-names>B</given-names></name>
</person-group>. <article-title>Immunohistochemical staining for androgen receptors: a sensitive marker of sebaceous differentiation</article-title>. <source>Am J Dermatopathol</source>. <year>1999</year>;<volume>21</volume>: <fpage>426</fpage>-<lpage>431</lpage>.</citation>
</ref>
<ref id="bibr70-1066896911417711">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kariya</surname><given-names>Y</given-names></name>
<name><surname>Moriya</surname><given-names>T</given-names></name>
<name><surname>Suzuki</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Sex steroid hormone receptors in human skin appendages and its neoplasms</article-title>. <source>Endocrine J</source>. <year>2005</year>;<volume>52</volume>:<fpage>317</fpage>-<lpage>325</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>